Get access

In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation

Authors

  • Qianjun He,

    1. State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, Shanghai 200050, P. R. China
    Search for more papers by this author
  • Zhiwen Zhang,

    1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong-Zhi Road, Shanghai 201203, P. R. China
    Search for more papers by this author
  • Fang Gao,

    1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong-Zhi Road, Shanghai 201203, P. R. China
    Search for more papers by this author
  • Yaping Li,

    Corresponding author
    1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong-Zhi Road, Shanghai 201203, P. R. China
    • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong-Zhi Road, Shanghai 201203, P. R. China.
    Search for more papers by this author
  • Jianlin Shi

    Corresponding author
    1. State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, Shanghai 200050, P. R. China
    • State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, Shanghai 200050, P. R. China
    Search for more papers by this author

Abstract

The in vivo biodistribution and urinary excretion of spherical mesoporous silica nanoparticles (MSNs) are evaluated by tail-vein injection in ICR mice, and the effects of the particle size and PEGylation are investigated. The results indicate that both MSNs and PEGylated MSNs of different particle sizes (80–360 nm) distribute mainly in the liver and spleen, a minority of them in the lungs, and a few in the kidney and heart. The PEGylated MSNs of smaller particle size escape more easily from capture by liver, spleen, and lung tissues, possess longer blood-circulation lifetime, and are more slowly biodegraded and correspondingly have a lower excreted amount of degradation products in the urine. Neither MSNs nor PEGylated MSNs cause tissue toxicity after 1 month in vivo.

Get access to the full text of this article

Ancillary